Sinovac Biotech Operating Income Growth & History (SVA)

Sinovac Biotech's operating income was −$490.1M for fiscal 2025.

View full Sinovac Biotech company overview

Sinovac Biotech annual operating income history

Sinovac Biotech annual operating income

Fiscal yearPeriod endedOperating incomeChangeGrowth
20252025-12-31−$490.1M$15.4M
20242024-12-31−$505.5M$208.4M
20232023-12-31−$714.0M−$205.0M
20222022-12-31−$509.0M−$18.13B
20212021-12-31$17.62B$17.40B+8070.12%
20202020-12-31$215.6M$147.1M+214.52%
20192019-12-31$68.6M$23.2M+51.30%
20182018-12-31$45.3M−$101,000−0.22%
20172017-12-31$45.4M$44.9M+8911.31%
20162016-12-31$504,000−$3.2M−86.36%
20152015-12-31$3.7M$1.8M+96.02%
20142014-12-31$1.9M−$8.1M−81.05%
20132013-12-31$9.9M$31.1M
20122012-12-31−$21.2M−$24.5M
20112011-12-31$3.4M$16.7M
20102010-12-31−$13.4M−$55.5M
20092009-12-31$42.1M

Sinovac Biotech operating income trends

Over the last five fiscal years, Sinovac Biotech's operating income decreased from $215.6M to −$490.1M, a change of −$705.8M.

About the metric

What operating income means

Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.

Calculation and source

SEC-reported operating income

TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Sinovac Biotech source filings ↗

Community posts

It’s quiet here.

No posts about SVA yet. Start the conversation.

Write the first post